← Russell 3000 cross-section

HALO HALOZYME THERAPEUTICS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$12.2bn
Revenue TTM
$1.7bn
Net income TTM
$414m
Free cash flow
$806m
Composite score
65.0
Sector rank
#635

Valuation

P / E
29.4
EV / EBITDA
22.8
EV / sales
8.4
FCF yield
6.63%
Earnings yield vs 10-yr
-1.33pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
24.9%
EBITDA margin
36.8%
ROE
288.1%
ROIC
31.1%
Revenue growth
41.1%

Insider activity, last 90 days

Net open-market
$-10.75m
Buyers
0
Sellers
3

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In December 2025, we entered into a commercial license and supply agreement with Viatris under which we license and supply an auto-injector product for self-administered SC selatogrel for the treatment of acute myocardial infarction in adult patients. Results of Operations Three Months Ended June 30, 2026 Compared to Three Months Ended June 30, 2025 Royalties – Royalties were as follows (in thousands): The increase in royalties was primarily driven by continued sales uptake of ENHANZE partner products that have launched since 2020, predominantly VYVGART Hytrulo by argenx and DARZALEX SC by Janssen in all geographies and contributions from other recently launched products. …HALOZYME THERAPEUTICS, INC., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →